JP2017528461A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528461A5
JP2017528461A5 JP2017512983A JP2017512983A JP2017528461A5 JP 2017528461 A5 JP2017528461 A5 JP 2017528461A5 JP 2017512983 A JP2017512983 A JP 2017512983A JP 2017512983 A JP2017512983 A JP 2017512983A JP 2017528461 A5 JP2017528461 A5 JP 2017528461A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
cell
alkyl
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528461A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049225 external-priority patent/WO2016040508A1/en
Publication of JP2017528461A publication Critical patent/JP2017528461A/ja
Publication of JP2017528461A5 publication Critical patent/JP2017528461A5/ja
Pending legal-status Critical Current

Links

JP2017512983A 2014-09-10 2015-09-09 置換ピロリジンカルボキサミド化合物 Pending JP2017528461A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048763P 2014-09-10 2014-09-10
US62/048,763 2014-09-10
US201562146804P 2015-04-13 2015-04-13
US62/146,804 2015-04-13
PCT/US2015/049225 WO2016040508A1 (en) 2014-09-10 2015-09-09 Substituted pyrrolidine carboxamide compounds

Publications (2)

Publication Number Publication Date
JP2017528461A JP2017528461A (ja) 2017-09-28
JP2017528461A5 true JP2017528461A5 (enExample) 2018-10-18

Family

ID=55459531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512983A Pending JP2017528461A (ja) 2014-09-10 2015-09-09 置換ピロリジンカルボキサミド化合物

Country Status (6)

Country Link
US (2) US20170247326A1 (enExample)
EP (1) EP3193609A4 (enExample)
JP (1) JP2017528461A (enExample)
AU (1) AU2015315177A1 (enExample)
CA (1) CA2960277A1 (enExample)
WO (1) WO2016040508A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017002985A (es) 2014-09-10 2017-11-17 Epizyme Inc Inhibidores de smyd.
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
WO2016040502A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted cyclohexylamine compounds
JP2017528464A (ja) 2014-09-10 2017-09-28 エピザイム,インコーポレイティド 置換ピペリジン化合物
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
GB201912674D0 (en) * 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1428493A (en) * 1973-05-02 1976-03-17 Science Union & Cie Heterocyclic amides processes for their preparation and pharma ceutical compositions containing them
JPS52128368A (en) * 1976-04-15 1977-10-27 Yamanouchi Pharmaceut Co Ltd Novel carboxylic acid amide derivatives and their preparation
GR66581B (enExample) * 1978-02-21 1981-03-27 Delalande Sa
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
DE10148290A1 (de) * 2001-09-29 2003-04-17 Bayer Cropscience Gmbh Heterocyclische Amide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung
DE60235114D1 (de) * 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
JP2006519833A (ja) * 2003-03-11 2006-08-31 ファイザー・プロダクツ・インク トランスフォーミング成長因子(tgf)阻害剤としてのピラジン化合物
WO2004081011A1 (en) * 2003-03-14 2004-09-23 Avidex Limited Immunomodulating heterocyclic compounds
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
TW200604168A (en) * 2004-04-02 2006-02-01 Vertex Pharma Azaindoles useful as inhibitors of rock and other protein kinases
WO2006086609A2 (en) * 2005-02-10 2006-08-17 Axys Pharmaceuticals, Inc. Inhibitors of tryptase
WO2006107923A1 (en) * 2005-04-05 2006-10-12 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
MX2007011198A (es) * 2005-04-12 2007-10-17 Solvay Pharm Gmbh Derivados de los 2-(4-sulfonilamino)-3-3hidroxi-3,4-dihidro-2h- croman -6- ilo sustituidos con aminoalquil-amidometilo y medicamentos que contienen estos compuestos.
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
DE602007006833D1 (de) * 2006-10-24 2010-07-08 Janssen Pharmaceutica Nv Mtp-inhibierende tetrahydronaphthalin-1-carbonsäurederivate
EP1975165A1 (de) * 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
KR20100020487A (ko) * 2007-05-24 2010-02-22 와이어쓰 엘엘씨 히스타민-3 길항제로서 아자시클릴벤즈아미드 유도체
EP2178375B1 (en) * 2007-07-20 2014-09-24 Merck Sharp & Dohme Corp. Pyrazoloý1,5-a¨pyrimidine derivatives
EP2307378A1 (en) * 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
EP2320737B1 (en) * 2008-08-05 2013-07-17 Merck Sharp & Dohme Corp. Pyrazolo-[1,5-a]-pyridines as mark inhibitors
JP2013028538A (ja) * 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
KR102196374B1 (ko) * 2012-11-29 2020-12-31 케모센트릭스, 인크. Cxcr7 길항제

Similar Documents

Publication Publication Date Title
JP2017528461A5 (enExample)
JP2017538659A5 (enExample)
JP2017511801A5 (enExample)
AU2017221802B2 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
US9546156B2 (en) N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
Garella et al. Microwave-assisted synthesis of N-heterocycles in medicinal chemistry
US9981959B2 (en) Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
JP5256047B2 (ja) ピロロ[3,2−c]ピリジン−4−オン2−インドリノン(indolinone)プロテインキナーゼ阻害剤
US9969694B2 (en) N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN112601747B (zh) 作为malt1抑制剂的吡唑衍生物
JP2017528460A5 (enExample)
CZ20001709A3 (cs) Deriváty thienopyrimidu a thienopyridinu, farmaceutické kompozice a způsoby léčení na jejich bázi
US20160280692A1 (en) N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
JP2017538659A (ja) Smyd阻害剤
EP3033342A1 (en) Annelated pyrroles and their use as crac inhibitors
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP2017528461A (ja) 置換ピロリジンカルボキサミド化合物
JP2017527577A (ja) 置換ピロリジン化合物
JP2017526706A5 (enExample)
JP2017527576A5 (enExample)
US20230095520A1 (en) Pharmaceutical composition for preventing or treating cancer comprising azole derivatives or pharmaceutically acceptable salt thereof
WO2014034898A1 (ja) ピリジン誘導体及び医薬
CN117396468A (zh) 作为ron抑制剂的新型吡啶衍生化合物
JP7768592B2 (ja) 医薬化合物